Pivotal Phase II PACE Trial of Ponatinib in Patients with CML and Philadelphia Chromosome-Positive ALL: 12-Month Follow-Up
Cortes JE et al. A pivotal Phase 2 trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. Proc ASH 2012;Abstract 163.
Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.
|